Colitis Clinical Trials

9 recruiting

Colitis Trials at a Glance

277 actively recruiting trials for colitis are listed on ClinicalTrialsFinder across 6 cities in 65 countries. The largest study group is Not Applicable with 70 trials, with the heaviest enrollment activity in New York, Warsaw, and Miami. Lead sponsors running colitis studies include Takeda, AbbVie, and Eli Lilly and Company.

Treatments under study

About Colitis Clinical Trials

Looking for clinical trials for Colitis? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Colitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Colitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 277 trials

Recruiting
Phase 4

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Ulcerative Colitis
Eisai Korea Inc.94 enrolled19 locationsNCT06964113
Recruiting
Not Applicable

Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults

Ulcerative Colitis (UC)Mb Crohn
Region Skane160 enrolled1 locationNCT07389161
Recruiting
Phase 3

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis
Sanofi671 enrolled20 locationsNCT07185009
Recruiting
Phase 3

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's DiseaseUlcerative Colitis
Takeda240 enrolled98 locationsNCT05442567
Recruiting

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)Inflammatory Bowel Syndrome
American Laboratory Products Company220 enrolled3 locationsNCT06810518
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis

Colitis Ulcerative
Sanofi204 enrolled115 locationsNCT06867094
Recruiting
Phase 3

Vancomycin Taper to Prevent Recurrent Clostridioides Difficile

Clostridia Difficile Colitis
McGill University Health Centre/Research Institute of the McGill University Health Centre500 enrolled1 locationNCT07328971
Recruiting

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

Ulcerative Colitis
Pfizer4,000 enrolled1 locationNCT07177209
Recruiting
Phase 3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis
Sanofi980 enrolled191 locationsNCT07184996
Recruiting
Phase 2

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

ColitisInflammatory Bowel DiseasesUlcerative Colitis
Spyre Therapeutics, Inc.645 enrolled175 locationsNCT07012395
Recruiting

Predictors of Prognosis in IBD Patients

Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis
Seoul National University Bundang Hospital100 enrolled1 locationNCT05653011
Recruiting
Not Applicable

IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms

Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis
University of Michigan68 enrolled1 locationNCT06094608
Recruiting
Phase 3

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche100 enrolled9 locationsNCT07158242
Recruiting
Phase 2

A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis

Ulcerative Colitis
Sanofi99 enrolled67 locationsNCT06975722
Recruiting
Not Applicable

Efficacy and Safety of Vedolizumab Combined With Upadacitinib in Patients With Ulcerative Colitis

Ulcerative Colitis (UC)
Sixth Affiliated Hospital, Sun Yat-sen University334 enrolled1 locationNCT06095596
Recruiting
Phase 4

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Crohn's DiseaseUlcerative Colitis
Takeda400 enrolled98 locationsNCT06581328
Recruiting

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

Inflammatory Bowel DiseasesCrohn DiseaseUlcerative Colitis+9 more
Seattle Children's Hospital200 enrolled1 locationNCT06315179
Recruiting
Not Applicable

WithHolding Enteral Feeds Around Blood Transfusion (International)

Necrotizing Enterocolitis
IWK Health Centre4,333 enrolled40 locationsNCT05213806
Recruiting

Association Between LRG and Histologic Remission in Ulcerative Colitis

Ulcerative Colitis in Histologic Remission
Showa Inan General Hospital100 enrolled1 locationNCT06372613
Recruiting
Phase 4

Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis(UPRISE)

Acute Severe Ulcerative Colitis
Xijing Hospital of Digestive Diseases226 enrolled4 locationsNCT07550673